B

BioNote Inc
KRX:377740

Watchlist Manager
BioNote Inc
KRX:377740
Watchlist
Price: 4 860 KRW 1.89% Market Closed
Market Cap: 495.6B KRW
Have any thoughts about
BioNote Inc?
Write Note

BioNote Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BioNote Inc
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
B
BioNote Inc
KRX:377740
Cash Equivalents
â‚©131.9B
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Cash Equivalents
-â‚©440
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SK Bioscience Co Ltd
KRX:302440
Cash Equivalents
â‚©127B
CAGR 3-Years
72%
CAGR 5-Years
95%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Cash Equivalents
â‚©182.9B
CAGR 3-Years
61%
CAGR 5-Years
4%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Cash Equivalents
â‚©10.6B
CAGR 3-Years
-31%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Cash Equivalents
â‚©27B
CAGR 3-Years
15%
CAGR 5-Years
22%
CAGR 10-Years
N/A
No Stocks Found

BioNote Inc
Glance View

Market Cap
496B KRW
Industry
Biotechnology

BioNote, Inc. develops veterinary diagnostic composition. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2022-12-22. The firm is engaged in the manufacture and sale of rapid diagnostic kits for humans, diagnosis raw materials such as antigens, antibody cell lines, standards, enzymes and others as well as semi-finished products. The firm is also engaged in the manufacture and sale of rapid immunochemical diagnosis, enzyme immune rebound protein, immunochemical fluorescence diagnosis and other products used for animals.

Intrinsic Value
4 469.88 KRW
Overvaluation 8%
Intrinsic Value
Price
B

See Also

What is BioNote Inc's Cash Equivalents?
Cash Equivalents
131.9B KRW

Based on the financial report for Dec 31, 2023, BioNote Inc's Cash Equivalents amounts to 131.9B KRW.

What is BioNote Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 3Y
2%

Over the last year, the Cash Equivalents growth was -81%. The average annual Cash Equivalents growth rates for BioNote Inc have been 2% over the past three years .

Back to Top